# Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

> **NCT01389310** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 249 (actual)

## Conditions studied

- HIV Infection

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01389310
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2014-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01389310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01389310, "Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01389310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*